Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 18, 2022.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
The annual Muscular Dystrophy Association's Clinical & Scientific Conference took place this week, March 13-16. The NeurologyLive® team was on-site and is providing coverage, including in-depth conversations with experts and opinion leaders, as well as the latest on data readouts and sessions.
The neurologist and assistant professor at the University of Toronto discussed the advantages hyperspectral retinal imaging tools like RetiSpec offer to clinical care, and when clinicians can expect to see them become commonplace in the diagnosis of AD.
Newly announced long-term findings from the pivotal phase 3 EMERGE and ENGAGE studies and phase 1b PRIME study showed that treatment with the 100 mg/mL injection significantly reduced amyloid-β plaque levels over 2 years of follow-up.
In Episode 7 of this NeurologyLive® Peers & Perspectives series, "Parkinson Disease: Managing Off-Episodes," Cynthia Comella, MD, discusses the importance of having COMT inhibitors as a therapeutic option for patients with Parkinson’s disease that are having off-episodes.
In Episode 2 of this NeurologyLive® Insights series, "Management of Multiple Sclerosis in the Era of COVID-19 Pandemic," Klaus Schmierer, MBBS, PhD, FRCP, introduces the disease-modifying therapies (DMT) that are available for patients with MS and their impact on the immune system.